DP
REGN icon

DDD Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

DDD Partners’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$20.8M Buy
26,920
+2,846
+12% +$2.18M 1.43% 13
2025
Q4 		$18.6M Buy
24,074
+2,713
+13% +$1.84M 1.18% 26
2025
Q3 		$12M Buy
21,361
+865
+4% +$489K 0.76% 39
2025
Q2 		$10.8M Buy
+20,496
New +$11.4M 1.15% 33

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

DDD Partners's REGN Position: Q1 2026 in Review

DDD Partners increased its Regeneron Pharmaceuticals (REGN) stake by 12% in Q1 2026, buying an estimated $2.18M and bringing the position to 26,920 shares worth $20.8M. The position accounts for 1.43% of the portfolio, ranked #13.

DDD Partners first reported a position in REGN in Q2 2025 and has held it in 4 quarters since. 1,393 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • DDD Partners held 26,920 shares of Regeneron Pharmaceuticals worth $20.8M as of Q1 2026.
  • DDD Partners bought 2,846 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $2.18M.
  • Regeneron Pharmaceuticals made up 1.43% of DDD Partners's portfolio in Q1 2026, its #13 holding.
  • DDD Partners first reported a position in Regeneron Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
  • 1,393 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on DDD Partners's 13F filing for Q1 2026, filed 28 Apr 2026.